Related Experiment Video

Updated: May 10, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An update on clinical trials in the treatment of advanced hepatocellular carcinoma

Jean K Lee1, Ghassan K Abou-Alfa

  • 1Memorial Sloan-Kettering Cancer Center, Cornell University, New York, NY 10065, USA.

Journal of Clinical Gastroenterology
|June 12, 2013
PubMed

Insights

Sorafenib offers modest benefits for advanced hepatocellular carcinoma (HCC). New therapies are urgently needed due to high mortality and unknown resistance mechanisms, justifying ongoing clinical trials for this challenging cancer.

Area of Science:

  • Hepatocellular Carcinoma (HCC) Research
  • Molecular Oncology
  • Drug Resistance Mechanisms

Background:

  • Sorafenib is FDA-approved for advanced hepatocellular carcinoma (HCC), yet provides limited clinical benefit.
  • Patients with advanced HCC face high mortality and poor prognosis.
  • The molecular mechanisms of sorafenib action and resistance in HCC are not well understood.

Purpose of the Study:

  • To highlight the critical need for novel therapeutic strategies in advanced HCC.
  • To underscore the justification for current and future clinical trials investigating new HCC treatments.

Main Methods:

  • Review of existing literature on sorafenib efficacy and resistance in HCC.
  • Analysis of the current treatment landscape for advanced HCC.
  • Identification of knowledge gaps in sorafenib's mechanism of action and resistance.

Main Results:

  • Sorafenib's modest clinical benefits in advanced HCC are confirmed.
  • Significant gaps exist in understanding the molecular basis of sorafenib's effectiveness and resistance.
  • Lack of alternative first-line and standard second-line therapies is evident.

Conclusions:

  • There is a pressing need for innovative therapeutic approaches for advanced HCC.
  • Ongoing and planned clinical trials are essential to address the limitations of current treatments.
  • Further research into HCC molecular mechanisms is crucial for developing more effective therapies.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...